Affinage

TFCP2

Alpha-globin transcription factor CP2 · UniProt Q12800

Length
502 aa
Mass
57.3 kDa
Annotated
2026-06-10
100 papers in source corpus 43 papers cited in narrative 43 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TFCP2 (LSF/CP2/LBP-1c) is a sequence-specific RNA Pol II transcription factor that recognizes directly-repeated GC-rich bipartite motifs and activates transcription by accelerating TFIIB recruitment to committed templates (PMID:2159933, PMID:1313810). It engages DNA as a higher-order oligomer—a dimer in solution that assembles into a tetramer for high-affinity binding—through DNA-binding and dimerization domains conserved with the Grainyhead/Elf-1/NTF-1 family, whose immunoglobulin-like fold and arginine-mediated DNA contacts are defined structurally in related Grhl proteins (PMID:8035790, PMID:9668115, PMID:9753426, PMID:29309642). Its activity is gated by mitogen-driven phosphorylation: ERK modifies S291 and rapidly increases DNA binding in stimulated T lymphocytes, though this modification is necessary but not sufficient for activation in fibroblasts, while cyclin C/CDK2 (CDK3) phosphorylation at S309 in early G1 inhibits transactivation (PMID:9192871, PMID:12858339, PMID:19237534). TFCP2 drives the G1/S transition by directly transactivating thymidylate synthase, and its inhibition triggers thymineless death or mitotic catastrophe with chromosome misalignment, multinucleation, and apoptosis (PMID:10970859, PMID:32539694). It functions combinatorially with lineage- and context-specific partners: it requires a ~40–45 kDa partner and CP2b/PIAS1 to form the erythroid stage-selector and alpha-globin activating complexes, cooperates with GATA-1 at erythroid regulatory elements, and partners with YY1 to recruit HDAC1 and repress the HIV-1 LTR (PMID:7828600, PMID:16648487, PMID:10888618, PMID:15988015, PMID:10995745). TFCP2 acts as an oncogene in hepatocellular carcinoma by directly upregulating osteopontin, MMP-9, FN1, and TJP1 to drive angiogenesis and metastasis, and stabilizes and co-activates YAP through a WW-PSY interaction to support YAP-TEAD transcription (PMID:20404171, PMID:22167195, PMID:25609232, PMID:29091762). Mutations disrupting a TFCP2 binding site in the uroporphyrinogen III synthase erythroid promoter reduce its expression and cause congenital erythropoietic porphyria, and FUS-TFCP2 fusion proteins drive rhabdomyosarcoma by upregulating ALK, blocking myogenic differentiation, and inducing genomic instability (PMID:11254675, PMID:38168093). Beyond transcription, TFCP2 binds α-tubulin and SET8 to facilitate α-tubulin methylation at Lys311 (PMID:32111740).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1990 High

    Established TFCP2 as a sequence-specific factor that binds directly-repeated GC motifs and activates RNA Pol II transcription, defining its core biochemical identity.

    Evidence Protein purification, methylation interference, and in vitro transcription on the SV40 late promoter

    PMID:2159933

    Open questions at the time
    • Mechanism of transcriptional activation not yet resolved
    • No in vivo target genes identified
  2. 1992 High

    Cloning and reconstitution mapped the region sufficient for DNA recognition and showed the factor activates a physiological (alpha-globin) promoter, while the mechanism of activation was traced to accelerated TFIIB assembly.

    Evidence cDNA cloning, bacterial expression, domain truncation, and in vitro transcription kinetics with general factor titration

    PMID:1313810 PMID:1732747

    Open questions at the time
    • How TFIIB recruitment is accelerated mechanistically unresolved
    • Activation domain not finely mapped
  3. 1994 High

    Resolved the oligomeric basis of DNA binding—homodimerization through one of two Grainyhead-conserved regions—separating dimerization from DNA-contact functions.

    Evidence Epitope-counting EMSA, mutagenesis, and domain mapping across CP2 and Drosophila Grainyhead

    PMID:8035790 PMID:8196641

    Open questions at the time
    • No structural model of the domains
    • Role of N-terminal inhibitory domain not defined
  4. 1995 High

    Showed TFCP2 is combinatorial, requiring lineage-specific partners to assemble functional complexes such as the erythroid stage-selector protein.

    Evidence Biochemical purification, cross-linking, and antiserum immunodepletion of the SSP complex in K562 cells

    PMID:7828600

    Open questions at the time
    • Identity of the 40–45 kDa partner not molecularly defined
    • How partner switching is regulated unknown
  5. 1998 High

    Demonstrated that high-affinity binding requires tetramerization (distinguishing TFCP2 from its dimer-competent Drosophila ortholog) and identified the Fe65 adaptor as a partner with isoform-specific subcellular distribution.

    Evidence Truncation mutagenesis, cross-linking, yeast two-hybrid, co-IP, and subcellular fractionation

    PMID:9668115 PMID:9685356

    Open questions at the time
    • Functional consequence of Fe65 interaction unresolved
    • Regulation of tetramer assembly unknown
  6. 1997 High

    Defined a repressive role through cooperation with YY1 at the HIV-1 LTR, showing TFCP2 acts as both activator and repressor depending on partners.

    Evidence EMSA, transient transfection, and viral replication assays

    PMID:9371597

    Open questions at the time
    • Repression mechanism not yet linked to chromatin modifiers
  7. 2000 High

    Connected TFCP2 to cell cycle control by identifying thymidylate synthase as a direct G1/S target whose loss causes thymineless death, and uncovered HDAC1 recruitment as the molecular basis of LTR repression.

    Evidence Dominant-negative expression, rescue experiments, enzyme assays, and HDAC1 co-purification with the YY1-LSF complex

    PMID:10888618 PMID:10970859

    Open questions at the time
    • Full set of cell-cycle targets undefined
    • How activation vs. repression is partner-selected unresolved
  8. 2000 High

    Mouse knockout revealed functional redundancy, showing the paralog LBP-1a/NF2d9 compensates for TFCP2 loss in hematopoiesis and globin expression.

    Evidence Gene targeting in mice with EMSA, supershift, and recombinant protein binding

    PMID:10995745

    Open questions at the time
    • Non-redundant physiological roles of TFCP2 not isolated
    • Degree of compensation in other tissues untested
  9. 2005 High

    Defined the erythroid transcriptional network: TFCP2 interacts directly with GATA-1, requires the CP2b isoform plus PIAS1 cofactor for alpha-globin activation, and uses discrete surface motifs to engage HXPR-containing partners REST and YY1.

    Evidence Co-IP, GST pull-down, ChIP, yeast two-hybrid, peptide-motif mutagenesis, and reporter assays

    PMID:15720400 PMID:15988015 PMID:16648487

    Open questions at the time
    • Structural basis of motif recognition not resolved
    • How isoform choice is regulated unknown
  10. 1997 High

    Identified ERK as the kinase that phosphorylates TFCP2 at S291 to increase DNA binding upon T-cell mitogenic stimulation, establishing signal-dependent regulation, later shown to be cell-type dependent (insufficient alone in fibroblasts).

    Evidence EMSA, in vitro kinase assays, S291 mutagenesis, phosphatase treatment, and MEK/ERK inhibitors in primary cells and NIH 3T3

    PMID:12858339 PMID:9192871

    Open questions at the time
    • Cell-type-specific cofactor required for activation unidentified
    • How phosphorylation alters DNA-binding conformation unknown
  11. 2005 High

    Linked TFCP2 to HIV latency by showing opposing kinase control—ERK reduces and p38 increases LTR binding—with pharmacological consequences for viral reactivation from resting CD4+ T cells.

    Evidence EMSA, ChIP, kinase assays, p38 inhibitor/agonist, and HIV recovery from primary patient cells

    PMID:15857981

    Open questions at the time
    • p38 phosphorylation site not mapped
    • Therapeutic exploitation untested in vivo
  12. 2009 High

    Identified cyclin C/CDK2 (CDK3) phosphorylation at S309 in early G1 as an inhibitory brake that delays TFCP2 transactivation until G1/S, refining cell-cycle timing of its target gene induction.

    Evidence In vitro kinase assays, S309 mutagenesis, cyclin C siRNA, co-IP, and endogenous Tyms readout

    PMID:19237534

    Open questions at the time
    • How S309 dephosphorylation is timed at G1/S unresolved
    • Crosstalk with ERK phosphorylation unclear
  13. 2011 High

    Established TFCP2 as a hepatocellular carcinoma oncogene driving angiogenesis and metastasis through direct transcriptional targets OPN, MMP-9, FN1, and TJP1, with OPN-CD44-c-Met signaling as a downstream effector.

    Evidence Xenografts, ChIP-on-chip, ChIP-PCR, promoter reporters, loss-of-function rescue, and phospho-RTK array

    PMID:20404171 PMID:21703197 PMID:22167195 PMID:25609232

    Open questions at the time
    • What activates TFCP2 oncogenic program upstream unclear
    • Tissue-specificity of target selection unresolved
  14. 2012 High

    Provided a chemical-genetic tool (FQI1) that specifically inhibits TFCP2 DNA binding and selectively kills LSF-overexpressing HCC cells, validating TFCP2 as a druggable target.

    Evidence EMSA, ChIP, reporter assays, structure-activity analysis of 23 quinolinones, and xenografts

    PMID:22396589

    Open questions at the time
    • Binding site of FQI1 on TFCP2 not structurally defined
    • Selectivity over paralogs untested
  15. 2017 High

    Revealed a non-genomic stabilizing role in which TFCP2 supports YAP-dependent transcription via a WW-PSY interaction, blocking βTrCP-mediated YAP ubiquitination and facilitating YAP-TEAD binding.

    Evidence Co-IP, ubiquitination assays, ChIP co-occupancy, and reporter assays in liver cancer

    PMID:29091762

    Open questions at the time
    • Reciprocal regulation of TFCP2 by YAP partly addressed only later
    • Structural basis of WW-PSY interaction undefined
  16. 2020 High

    Extended TFCP2 function beyond transcription, showing it bridges SET8 and α-tubulin to facilitate Lys311 methylation, and demonstrated that TFCP2 loss causes mitotic catastrophe with chromosome misalignment.

    Evidence In vitro methylation reconstitution, MS, co-IP, GST pull-down, FQI1 inhibitor, and time-lapse microscopy comparing siRNA and FQI1

    PMID:32111740 PMID:32539694

    Open questions at the time
    • Whether tubulin methylation explains the mitotic phenotype unestablished
    • Substrate scope of TFCP2-SET8 axis unknown
  17. 2024 Medium

    Showed that TFCP2 transcriptional complexes are stabilized by ubiquitin signaling (TRAF6 K63-ubiquitination of YAP1) to drive PD-L1, and that FUS-TFCP2 fusion proteins act as oncogenic drivers in rhabdomyosarcoma.

    Evidence CRISPRi screen, K63-specific ubiquitination assays, co-IP, PD-L1 flow cytometry, fusion-protein expression, and DNA repair assays

    PMID:38168093 PMID:38583649

    Open questions at the time
    • Single-lab findings without independent replication
    • Mechanism of fusion-driven genomic instability undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How TFCP2 selects between its activating, repressive, and protein-stabilizing roles in different tissues, and the high-resolution structure of human TFCP2 on DNA, remain unresolved.
  • No experimental structure of human TFCP2 itself (only Grhl family members)
  • Rules governing partner-selective activation vs. repression unknown
  • In vivo non-redundant roles obscured by paralog compensation

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 6 GO:0140110 transcription regulator activity 5 GO:0060090 molecular adaptor activity 4 GO:0140223 general transcription initiation factor activity 1
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 3 R-HSA-1643685 Disease 3 R-HSA-74160 Gene expression (Transcription) 3
Partners
FE65GATA-1PIAS1RESTSET8SREBP2YAP1YY1
Complex memberships
YAP1/TFCP2 transcriptional complexYY1-LSF-HDAC1 repressor complexstage selector protein (SSP) complex

Evidence

Reading pass · 43 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1990 LSF (TFCP2) was purified as a 63-kDa polypeptide that binds two distinct bipartite sites within the SV40 late promoter (LSF-GC site and LSF-280 site), recognizing directly repeated GC motifs with a center-to-center spacing of 10 bp, and activates transcription from the SV40 late promoter in vitro via binding to template DNA at initiation site L325. Protein purification, DNA affinity chromatography, methylation interference, in vitro transcription assay Genes & development High 2159933
1992 CP2 (TFCP2) was molecularly cloned; bacterial expression of the full-length 502-aa murine factor or a core region (aa 133–395) generated polypeptides with the DNA-binding specificity of CP2, delimiting the region sufficient for specific DNA sequence recognition. The factor activates transcription of alpha-globin promoter templates ~3–4 fold in vitro. cDNA cloning, bacterial expression, DNase I footprinting, EMSA, in vitro transcription Molecular and cellular biology High 1732747
1992 LSF (TFCP2) activates RNA polymerase II transcription by increasing the rate of association of TFIIB with the committed template on the SV40 major late promoter; LSF has no effect on TFIID binding rate or stability, but specifically accelerates the TFIIB assembly step. In vitro transcription kinetics, band mobility shift assays, general transcription factor titration The Journal of biological chemistry High 1313810
1993 CP2 (TFCP2) binds a hyphenated recognition sequence motif spanning one DNA helix turn; elevated CP2 levels (2.5–5.5-fold) in stably transformed cells increased alpha-globin promoter-driven reporter activity 3–6 fold in vivo, confirming direct transcriptional activation. DNase I footprinting, EMSA, stable/transient transfection, CAT reporter assay The Journal of biological chemistry High 8349681
1994 LSF (TFCP2) binds DNA as a homodimer, as demonstrated by an epitope-counting method. The alternatively spliced isoform LSF-ID lacks two beta-strand-forming regions conserved with Drosophila Elf-1/NTF-1; double amino acid substitutions in each of these regions eliminated specific DNA-binding activity. Mutations in one homology region, but not the other, eliminated dimerization. Epitope-counting EMSA, mutagenesis, protein-protein interaction studies Molecular and cellular biology High 8035790
1994 The DNA-binding and dimerization domains of Drosophila Grainyhead are conserved in human CP2 (TFCP2). The DNA-binding domain (263 aa) contains a smaller core; the major dimerization domain is in a separate region and is required to stabilize DNA interactions. An N-terminal inhibitory domain can modulate activity. Domain deletion mapping, DNA-binding assays, dimerization assays in Drosophila and vertebrate (CP2) proteins Molecular and cellular biology High 8196641
1995 CP2 (TFCP2) is pivotal to, but not sufficient for, the stage selector protein (SSP) complex that binds the stage selector element (SSE) in the gamma-globin promoter. CP2 requires a heterodimeric partner (~40–45 kDa) present in K562 cells to bind the SSE. The SSP complex is disrupted by anti-CP2 antiserum. The analogous chicken complex includes NF-E4, which is homologous to CP2. Biochemical purification, EMSA, UV and protein cross-linking, anti-CP2 antiserum disruption, Western blot The EMBO journal High 7828600
1997 LSF (TFCP2) and YY1 cooperate to form a complex that recognizes the initiation region of the HIV-1 LTR and cooperatively repress LTR transcription and viral replication; transient expression of LSF alone has no effect, but cooperation with YY1 is required for repression in vivo. EMSA, transient transfection, viral replication assay Journal of virology High 9371597
1997 LSF (TFCP2) DNA-binding activity is rapidly and quantitatively increased (~5-fold within 15 min) by mitogenic stimulation of resting human peripheral T lymphocytes, correlating with phosphorylation-induced reduction in LSF electrophoretic mobility. ERK1 (pp44) phosphorylates LSF in vitro at the same residue phosphorylated in vivo (position 291). Phosphatase treatment in vitro increases LSF mobility and decreases DNA-binding activity, confirming that phosphorylation directly increases DNA-binding. EMSA, in vitro kinase assay, mutagenesis (S291 mutant), phosphatase treatment, primary T lymphocyte stimulation Genes & development High 9192871
1998 LSF (TFCP2) binds DNA as a tetramer (larger than a dimer) for high-affinity binding, requiring 234–320 amino acids. NTF-1 (Drosophila ortholog) can bind an LSF half-site as a dimer, whereas LSF cannot, indicating different oligomerization requirements despite shared DNA-binding domains. Truncation mutagenesis, EMSA, cross-linking experiments, mixing assays with full-length and truncation mutants The Journal of biological chemistry High 9668115
1998 The Fe65 adaptor protein interacts with CP2/LSF/LBP1 (TFCP2) through its N-terminal PID1 domain, as shown by yeast two-hybrid and co-immunoprecipitation of native molecules. Different isoforms of CP2/LSF/LBP1 are distributed differently among subcellular fractions; at least one splice isoform (LSF-ID) is present outside the nucleus, while Fe65 is found in both nuclear and non-nuclear fractions. Interaction trap (yeast two-hybrid), co-immunoprecipitation, subcellular fractionation, transfection with HA-tagged constructs The Journal of biological chemistry High 9685356
1998 Chicken CP2 (cCP2, TFCP2) forms a tetramer as shown by EMSA and cross-linking experiments. cCP2 is essential for transcription through the alphaA-crystallin lens enhancer alphaCE1; lens-specific enhancer activity depends on a 6-bp sequence (LSE) adjacent to the CP2 binding site, suggesting cooperation between cCP2 tetramer and a lens-specific factor binding LSE. EMSA, protein cross-linking, overexpression/dominant negative transfection, element substitution experiments Genes to cells High 9753426
2000 LSF (TFCP2) binds sites within the thymidylate synthase (TS) promoter and intronic regions required for G1-S induction. Expression of dominant-negative LSF prevents the increase in TS enzyme levels during G1-S and induces S-phase-dependent apoptosis (thymineless death), which can be rescued by thymidine supplementation or heterologous TS expression. Reporter mutation analysis, dominant-negative expression, enzyme activity assay, apoptosis assays, rescue experiments The EMBO journal High 10970859
2000 YY1 and LSF (TFCP2) cooperate to recruit HDAC1 to the HIV-1 LTR; HDAC1 co-purifies with the LTR-bound YY1-LSF repressor complex. LSF recruits YY1 to the LTR via YY1's zinc fingers (first two zinc fingers sufficient in vitro). The HDAC1-interacting domain of YY1 is required for LTR repression, and HDAC inhibitor trichostatin A blocks YY1-mediated repression. Co-purification, EMSA, HDAC inhibitor (TSA) treatment, deletion mutant analysis, HDAC1 overexpression Journal of virology High 10888618
2000 Targeted disruption of CP2 (TFCP2) in mice produces viable animals with no apparent defects in hematopoiesis, globin gene expression, or immune responses. In CP2-null extracts, a slower-migrating complex bound to CP2 consensus sites is recognized by anti-NF2d9 (LBP-1a) antiserum, and recombinant LBP-1a can bind CP2 sites and form complexes with CP2 heteromeric partners, indicating functional compensation by the paralog LBP-1a/NF2d9. Gene targeting (knockout mice), EMSA with nuclear extracts, antiserum supershift, recombinant protein binding assay The Journal of biological chemistry High 10995745
2001 Mutations in a putative CP2 (TFCP2) binding motif (-90C to A) in the uroporphyrinogen III synthase erythroid-specific promoter alter CP2 binding (EMSA) and reduce promoter activity to ~8% of wild-type in K562 cells, causing congenital erythropoietic porphyria. An adjacent -86A mutation does not alter CP2 binding. Sequencing, luciferase reporter assay, EMSA The Journal of clinical investigation High 11254675
2003 LSF (TFCP2) is rapidly and quantitatively phosphorylated upon growth induction in NIH 3T3 cells; ERK is responsible for this phosphorylation, as shown by correlation of ERK activity with LSF phosphorylation and by specific MEK/ERK pathway inhibitors blocking LSF modification. ERK phosphorylation is necessary but not sufficient for activation of LSF DNA-binding activity (DNA-binding is not significantly altered in fibroblasts despite phosphorylation). Electrophoretic mobility shift, in vitro kinase assay, pharmacological inhibitors of Ras/Raf/MEK/ERK, cell fractionation Journal of cellular biochemistry High 12858339
2005 CP2 (TFCP2) binds erythroid regulatory regions of the GATA-1, EKLF, and p45 NF-E2 genes and forms a ternary complex with GATA-1 and DNA at the GATA-1 HS2 enhancer. CP2 physically interacts with GATA-1 (demonstrated by co-immunoprecipitation and GST pull-down). Both factors occupy the same regulatory elements in vivo (chromatin IP). Mutation of the CP2 consensus in these elements severely impairs enhancer activity in K562 cells. EMSA, ChIP, co-immunoprecipitation, GST pull-down, transient transfection reporter assays Molecular and cellular biology High 16648487
2005 Two HXPR-motif-containing proteins, REST and YY1, bind CP2 (TFCP2) via their HXPR sequences; GST pull-down and co-immunoprecipitation confirm this interaction. Double amino acid substitution in the HXPR sequence of YY1 abolishes binding to CP2 and eliminates YY1's suppression of CP2 transcriptional activity. At least three distinct binding regions on CP2 accommodate four different peptide motifs (HXPR, PHL, ASR, PXHXH). Peptide library screen, GST pull-down, co-immunoprecipitation, site-directed mutagenesis, transcriptional reporter assay The FEBS journal High 15720400
2005 Erythroid cell-specific alpha-globin transactivation by CP2 (TFCP2) requires specific splice variants: CP2b (with an extra 36-aa exon) forms heteromeric complexes with CP2c; this heterodimer activates alpha-globin specifically in erythroid cells but not in non-erythroid 293T cells. Addition of PIAS1 (identified as a CP2-binding protein by yeast two-hybrid and confirmed by co-immunoprecipitation) restores alpha-globin activation in 293T cells, identifying PIAS1 as the missing erythroid cofactor. Yeast two-hybrid, co-immunoprecipitation, luciferase reporter in erythroid and non-erythroid cells, expression of recombinant isoforms Molecular and cellular biology High 15988015
2006 APLP2 intracellular C-terminal domain (ICD) interacts with CP2 (TFCP2) in the nucleus and induces expression of GSK-3β. Nuclear colocalization and interaction were demonstrated, and GSK-3β protein levels increased upon APLP2-ICD expression. Co-immunoprecipitation, transfection, immunofluorescence, Western blot Cell death and differentiation Medium 16645641
2009 LSF (TFCP2) is phosphorylated by cyclin C/CDK2 (and cyclin C/CDK3 in humans) predominantly at S309 during early G1 after mitogenic stimulation of quiescent fibroblasts. This phosphorylation is mediated by cyclin C-dependent kinases (confirmed by co-immunoprecipitation and siRNA knockdown of cyclin C), and phosphorylation at S309 inhibits LSF transactivation and prevents induction of the LSF target gene Tyms at G1/S. In vitro kinase assays, mutagenesis (S309), co-immunoprecipitation, siRNA knockdown of cyclin C, transient transfection reporter, endogenous Tyms expression Molecular and cellular biology High 19237534
2005 LSF (TFCP2) binds the HIV-1 LTR as a tetramer; ERK phosphorylation of LSF decreases its binding to the LTR in vitro, while p38 phosphorylation increases binding. In cells, p38 agonist increases LSF occupancy at LTR chromatin; p38 inhibition decreases LSF occupancy, increases histone H4 acetylation at the adjacent nucleosome, blocks YY1-mediated LTR repression, and results in recovery of HIV from resting CD4+ T cells of aviremic donors. EMSA, ChIP, kinase assays, pharmacological p38 inhibition/agonism, HIV recovery assay from primary cells Journal of virology High 15857981
2010 LSF (TFCP2) functions as an oncogene in hepatocellular carcinoma: LSF overexpression promotes aggressive, angiogenic, and multiorgan metastatic tumors in nude mice, while inhibition abrogates growth and metastasis. LSF transcriptionally upregulates osteopontin (OPN), which mediates key oncogenic functions; loss of OPN impairs LSF-driven tumorigenesis. Stable overexpression/dominant-negative, nude mouse xenograft, microarray, loss-of-function studies with siRNA/shRNA Proceedings of the National Academy of Sciences of the United States of America High 20404171
2011 LSF (TFCP2) transcriptionally upregulates MMP-9 to enhance angiogenesis in HCC. ChIP-on-chip identified MMP-9 as a direct LSF target; ChIP confirmed LSF binding to the MMP-9 promoter. Deletion mutation analysis identified LSF-responsive promoter regions. MMP-9 inhibition abrogated LSF-induced angiogenesis and tumorigenesis in vivo. ChIP-on-chip, ChIP-PCR, promoter deletion reporter assays, HUVEC differentiation assay, CAM assay, nude mouse xenograft The Journal of biological chemistry High 22167195
2011 LSF (TFCP2) activates c-Met signaling in HCC through a pathway involving LSF-driven OPN secretion activating c-Met via CD44. Co-immunoprecipitation confirmed OPN-induced CD44/c-Met interaction. Chemical or genetic inhibition of c-Met abrogates LSF-mediated tumorigenesis and metastasis in vivo. Phospho-RTK array, co-immunoprecipitation, tissue microarray IHC, siRNA, chemical inhibitor, nude mouse xenograft Journal of hepatology Medium 21703197
2015 TFCP2 directly regulates FN1 (fibronectin 1) and TJP1 (tight junction protein 1) as transcriptional targets mediating HCC metastasis. ChIP-on-chip combined with transcriptome analysis identified these targets; ChIP-PCR confirmed TFCP2 binding to the FN1 promoter, and promoter reporter identified TFCP2-binding motifs. FN1 inhibition blocks TFCP2-induced aggression; TFCP2 overexpression rescues FN1 inhibition. ChIP-on-chip, transcriptome microarray, ChIP-PCR, promoter reporter assay, siRNA rescue experiments Journal of experimental & clinical cancer research High 25609232
2016 LSF (TFCP2) inhibits melanoma cell growth by binding within a 150-bp upstream region of the p21CIP1 transcription start site and increasing p21CIP1 expression, resulting in G1 phase arrest. EMSA and ChIP assays confirmed LSF binding to the p21CIP1 promoter. EMSA, ChIP, overexpression/depletion, cell cycle analysis, anchorage-dependent/independent growth assays, xenograft Oncotarget High 26506241
2017 TFCP2 is required for YAP-dependent transcription in liver cancer. Mechanistically, TFCP2 stimulates YAP function via a WW-PSY interaction, maintains YAP stability by inhibiting βTrCP-mediated ubiquitination, and acts as a transcription co-factor facilitating YAP binding to YBF-containing transcription factors and the YAP-TEAD interaction. Genomic co-occupancy of YAP and TFCP2 was revealed by ChIP. Co-immunoprecipitation (WW-PSY interaction), ubiquitination assays, ChIP, luciferase reporter, siRNA/overexpression Cell reports High 29091762
2018 Crystal structures of the DNA-binding domains of Grainyhead-like (Grhl) 1 and Grhl2 (close CP2/TFCP2 family members) reveal an immunoglobulin-like core fold shared with p53, with dimeric DNA binding mediated by two conserved arginine residues. A cancer-associated mutation in Grhl1 at one of these arginines completely abrogates DNA binding in biochemical assays and transcriptional activation in human cells. X-ray crystallography, in vitro DNA-binding assays, cancer-mutation analysis, transcriptional reporter assay in human cell line Nucleic acids research High 29309642
2017 TFCP2 promotes pancreatic cancer progression by interacting with β-catenin, enhancing the β-catenin/TCF4 interaction, and activating β-catenin/TCF signaling, as demonstrated by co-immunoprecipitation and luciferase reporter assay. Co-immunoprecipitation, luciferase reporter (β-catenin/TCF), overexpression/knockdown, colony formation, in vivo metastasis model Oncotarget Medium 29050300
2019 CCT3 co-interacts with YAP and TFCP2 (confirmed by mass spectrometry co-immunoprecipitation) and prolongs their half-lives by blocking PCBP2-induced ubiquitination in a βTrCP-independent manner. PCBP2 directly interacts with YAP via a WB motif-WW domain interaction and indirectly with TFCP2 via YAP. CCT3 separates PCBP2-YAP interactions, preventing ubiquitination of both YAP and TFCP2. Mass spectrometry co-immunoprecipitation, ubiquitination assays, co-immunoprecipitation, Western blot half-life assay Cell death & disease Medium 31501420
2020 TFCP2 directly bound the promoters of EGF and TGFα to regulate their expression, stimulating autocrine EGFR signaling and AKT activation in triple-negative breast cancer. This creates a positive feedback loop controlling TFCP2-mediated EMT, stemness, and metastasis. ChIP, promoter reporter assay, siRNA/overexpression, EGFR signaling assays, in vivo metastasis model Cancer research Medium 32193292
2020 LSF (TFCP2) binds α-tubulin and SET8 (KMT5A/PR-Set7), facilitating SET8-mediated methylation of α-tubulin at Lys311. LSF enhances SET8-mediated α-tubulin methylation in vitro; the LSF inhibitor FQI1 counters this facilitation. SET8 bound α-tubulin and methylated it at Lys311 as shown by in vitro radiolabeling, MS, and immunoblotting. In vitro radiolabeling, mass spectrometry, immunoblotting, co-immunoprecipitation, immunofluorescence, GST pull-down, FQI1 inhibitor The Journal of biological chemistry High 32111740
2020 Inhibition of LSF (TFCP2) by either the small molecule FQI1 or siRNA causes highly similar mitotic delays with condensed, unaligned chromosomes preceding metaphase, leading to multi-nucleation, apoptosis, and senescence. The concordance between FQI1 and siRNA phenotypes confirms LSF as the specific cellular target of FQI1. Time-lapse microscopy, bulk cell synchronization, siRNA knockdown vs. FQI1 treatment comparison, cell death/senescence assays BMC cancer High 32539694
2009 TFCP2 acts as a transcription factor that directly binds the SRY promoter (demonstrated by EMSA); TFCP2 suppression by RNAi significantly reduced SRY mRNA expression in cells, while overexpression did not significantly increase SRY mRNA, indicating TFCP2 is required but not limiting for SRY expression. EMSA, RNAi knockdown, overexpression, RT-PCR Molecular and cellular biochemistry Medium 19902333
2021 TFCP2 interacts with SREBP2 (co-immunoprecipitation) and synergistically activates expression of HMGCR (a rate-limiting enzyme in cholesterol synthesis), enabling pancreatic cancer cells to overcome oncogene-induced senescence. Statins (which inhibit HMGCR) reversed the anti-senescence effect of TFCP2. Co-immunoprecipitation, qRT-PCR, luciferase reporter, statin treatment, senescence assays (SA-β-gal) Frontiers in oncology Medium 34804919
2022 TFCP2 induces SMAD2 expression as a transcription factor; ITGA2 inhibits the nuclear translocation of TFCP2, thereby reducing SMAD2 transcription and suppressing TGF-β pathway activation. Co-immunoprecipitation and nuclear/cytoplasmic fractionation confirmed that ITGA2 interacts with and retains TFCP2 in the cytoplasm. Co-immunoprecipitation, nuclear/cytoplasmic fractionation, ChIP, luciferase reporter, Western blot, RT-qPCR Journal of experimental & clinical cancer research Medium 35193647
2022 TFCP2 interacts with ATF3 to cooperatively regulate de novo serine synthesis by promoting ATF3 binding to the PHGDH promoter. Knockdown of TFCP2 significantly inhibited ATF3 binding to the PHGDH promoter, as shown by ChIP. Co-immunoprecipitation, ChIP, siRNA knockdown, cell proliferation and sphere formation assays Experimental cell research Medium 35421367
2024 TRAF6 stabilizes YAP1 by K63 poly-ubiquitination, promoting formation of the YAP1/TFCP2 transcriptional complex and subsequent PD-L1 transcription in melanoma. Suppression of TRAF6 down-regulates PD-L1 on the membrane surface of melanoma cells. In vitro and in vivo assays confirmed the TRAF6→YAP1 K63-ubiquitination→YAP1/TFCP2 complex→PD-L1 transcription axis. CRISPR interference screen, ubiquitination assays (K63-specific), co-immunoprecipitation, PD-L1 flow cytometry, luciferase reporter, in vitro/in vivo tumor models Cancer letters Medium 38583649
2024 FUS-TFCP2 fusion protein blocks myogenic differentiation, induces transcription of ALK and truncated TERT, and inhibits DNA repair in rhabdomyosarcoma. Functional studies in cell models showed genomic instability and signs of defective homologous recombination in TFCP2-rearranged tumors. Functional cell-based studies with FUS-TFCP2 expression constructs, transcriptome analysis, DNA repair assays Nature communications Medium 38168093
2017 CP2 (TFCP2) upregulates miR-144 expression in mouse ovarian granulosa cells by directly binding the miR-144 promoter, as shown by luciferase reporter, ChIP, and EMSA. CP2-driven miR-144 expression suppresses COX-2 and reduces PGE2 production. Luciferase reporter, ChIP, EMSA, miR-144 inhibitor/mimic overexpression Cell death & disease Medium 28182010
2012 The small molecule FQI1 inhibits LSF (TFCP2) DNA-binding activity in vitro (EMSA) and in cells (ChIP), eliminates transcriptional stimulation of LSF-dependent reporter constructs, and induces rapid cell death in LSF-overexpressing HCC cells without affecting normal hepatocytes. Structure-activity relationships of 23 quinolinones are highly concordant between antiproliferative and LSF-inhibitory activities, confirming LSF as the specific target. EMSA, ChIP, luciferase reporter, cell viability assays, SAR analysis, xenograft mouse model Proceedings of the National Academy of Sciences of the United States of America High 22396589

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2000 The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. Journal of virology 303 10888618
1998 The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1. The Journal of biological chemistry 135 9685356
2019 A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 117 31383960
1995 Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmentally specific protein. The EMBO journal 101 7828600
2018 Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochemical and biophysical research communications 92 29738762
1992 Molecular cloning of the alpha-globin transcription factor CP2. Molecular and cellular biology 90 1732747
1997 Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. Journal of virology 89 9371597
2003 Functional conservation between members of an ancient duplicated transcription factor family, LSF/Grainyhead. Nucleic acids research 84 12888489
2021 Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology 76 33382123
2018 Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype. Histopathology 76 29758589
2018 TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer letters 74 29410248
2001 Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. The Journal of clinical investigation 73 11254675
1990 Transcription factor LSF binds two variant bipartite sites within the SV40 late promoter. Genes & development 73 2159933
2010 Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 70 20404171
1994 The Drosophila tissue-specific factor Grainyhead contains novel DNA-binding and dimerization domains which are conserved in the human protein CP2. Molecular and cellular biology 66 8196641
2000 Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. The EMBO journal 65 10970859
2000 The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Human molecular genetics 63 11001930
2020 Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases. Virchows Archiv : an international journal of pathology 59 32556562
1993 Characterization of the molecularly cloned murine alpha-globin transcription factor CP2. The Journal of biological chemistry 59 8349681
1994 An analytical edge spread function model for computer fitting and subsequent calculation of the LSF and MTF. Medical physics 58 7869985
2004 Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 55 15563829
2015 Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. Cancer letters 54 26723877
1994 One exon of the human LSF gene includes conserved regions involved in novel DNA-binding and dimerization motifs. Molecular and cellular biology 54 8035790
2019 CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell death & disease 53 31501420
1997 Mitogenic stimulation of resting T cells causes rapid phosphorylation of the transcription factor LSF and increased DNA-binding activity. Genes & development 53 9192871
2017 TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy. Cell reports 47 29091762
1998 LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein-DNA complex. The Journal of biological chemistry 47 9668115
2003 Association of the 3' UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's disease. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 44 12555245
1995 Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). British journal of pharmacology 44 7582456
1994 Characterization of the genomic structure, chromosomal location, promoter, and development expression of the alpha-globin transcription factor CP2. The Journal of biological chemistry 44 8157699
1989 Hydroxylation and Dechlorination of Tetrachlorohydroquinone by Rhodococcus sp. Strain CP-2 Cell Extracts. Applied and environmental microbiology 44 16347859
2012 The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. American journal of cancer research 43 22679558
2018 Structural basis of gene regulation by the Grainyhead/CP2 transcription factor family. Nucleic acids research 42 29309642
2000 CRTR-1, a developmentally regulated transcriptional repressor related to the CP2 family of transcription factors. The Journal of biological chemistry 41 11073954
1992 Activation of RNA polymerase II transcription by the specific DNA-binding protein LSF. Increased rate of binding of the basal promoter factor TFIIB. The Journal of biological chemistry 41 1313810
1998 Transcription factor CP2 is essential for lens-specific expression of the chicken alphaA-crystallin gene. Genes to cells : devoted to molecular & cellular mechanisms 40 9753426
2012 Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 37 22396589
2008 The fold recognition of CP2 transcription factors gives new insights into the function and evolution of tumor suppressor protein p53. Cell cycle (Georgetown, Tex.) 37 18787404
2011 Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). The Journal of biological chemistry 36 22167195
2010 The evolutionary diversification of LSF and Grainyhead transcription factors preceded the radiation of basal animal lineages. BMC evolutionary biology 35 20398424
2000 Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. The Journal of biological chemistry 35 10973979
2015 Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis. Journal of experimental & clinical cancer research : CR 33 25609232
2011 c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF. Journal of hepatology 33 21703197
2006 Intracellular domains of amyloid precursor-like protein 2 interact with CP2 transcription factor in the nucleus and induce glycogen synthase kinase-3beta expression. Cell death and differentiation 33 16645641
1988 Hydrogen-1 nuclear magnetic resonance of the nitrogenase iron protein (Cp2) from Clostridium pasteurianum. Biochemistry 32 2847787
2018 Neglected Functions of TFCP2/TFCP2L1/UBP1 Transcription Factors May Offer Valuable Insights into Their Mechanisms of Action. International journal of molecular sciences 31 30241344
2000 Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors. The Journal of biological chemistry 31 10995745
2017 MicroRNA-144 is regulated by CP2 and decreases COX-2 expression and PGE2 production in mouse ovarian granulosa cells. Cell death & disease 30 28182010
2009 The male-determining gene SRY is a hybrid of DGCR8 and SOX3, and is regulated by the transcription factor CP2. Molecular and cellular biochemistry 30 19902333
2006 Functional interaction of CP2 with GATA-1 in the regulation of erythroid promoters. Molecular and cellular biology 30 16648487
2001 Cloning, expression and processing of the CP2 neuropeptide precursor of Aplysia. Peptides 30 11786187
2001 Genetic association of an LBP-1c/CP2/LSF gene polymorphism with late onset Alzheimer's disease. Journal of medical genetics 29 11283204
2005 Erythroid cell-specific alpha-globin gene regulation by the CP2 transcription factor family. Molecular and cellular biology 28 15988015
2019 Spindle cell rhabdomyosarcoma in a lumbar vertebra with FUS-TFCP2 fusion. Pathology, research and practice 27 30948206
2009 Transcription factors LSF and E2Fs: tandem cyclists driving G0 to S? Cell cycle (Georgetown, Tex.) 27 19556876
2004 A novel Cryptosporidium parvum antigen, CP2, preferentially associates with membranous structures. Parasitology research 27 14727189
2017 TFCP2 activates beta-catenin/TCF signaling in the progression of pancreatic cancer. Oncotarget 26 29050300
2003 Mammalian transcription factor LSF is a target of ERK signaling. Journal of cellular biochemistry 26 12858339
2024 TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma. Cancer letters 25 38583649
2022 Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis. Journal of experimental & clinical cancer research : CR 25 35193647
2021 DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter. Clinical epigenetics 25 33892791
2020 A Feedback Loop Comprising EGF/TGFα Sustains TFCP2-Mediated Breast Cancer Progression. Cancer research 25 32193292
2016 Transcription factor LSF (TFCP2) inhibits melanoma growth. Oncotarget 25 26506241
2013 Characterization of bacteriophages Cp1 and Cp2, the strain-typing agents for Xanthomonas axonopodis pv. citri. Applied and environmental microbiology 25 24123743
1996 Allograft acceptance and rejection, mediated by a liver suppressor factor, LSF-1, purified from serum of liver transplanted rats. Transplant immunology 25 8972558
1994 Effects of lung surfactant factor (LSF) treatment on gas exchange and histopathological changes in an animal model of adult respiratory distress syndrome (ARDS): comparison of recombinant LSF with bovine LSF. Pulmonary pharmacology 25 7626919
2006 Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes. Bioorganic & medicinal chemistry letters 24 16650991
2003 CP2 binding to the promoter is essential for the enhanced transcription of globin genes in erythroid cells. Molecules and cells 24 12661759
2011 Total synthesis of (-)-CP2-disorazole C1. Organic letters 23 21739942
1994 Evidence that levels of the dimeric cellular transcription factor CP2 play little role in the activation of the HIV-1 long terminal repeat in vivo or following superinfection with herpes simplex virus type 1. The Journal of biological chemistry 23 8063751
2024 Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nature communications 22 38168093
2023 C. elegans molting requires rhythmic accumulation of the Grainyhead/LSF transcription factor GRH-1. The EMBO journal 22 36688410
2022 EWSR1-TFCP2 in an adolescent represents an extremely rare and aggressive form of intraosseous spindle cell rhabdomyosarcomas. Cold Spring Harbor molecular case studies 22 35768243
2015 GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma. Oncotarget 22 26378040
2020 The microtubule-associated histone methyltransferase SET8, facilitated by transcription factor LSF, methylates α-tubulin. The Journal of biological chemistry 21 32111740
2007 CP2 gene as a useful viability marker for Cryptosporidium parvum. Parasitology research 21 18060431
2022 Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and ALK: Report of Three New Cases in the Head and Neck Region and Literature Review. Head and neck pathology 20 36374445
2009 Phosphorylation by cyclin C/cyclin-dependent kinase 2 following mitogenic stimulation of murine fibroblasts inhibits transcriptional activity of LSF during G1 progression. Molecular and cellular biology 19 19237534
2005 Identification and characterization of four novel peptide motifs that recognize distinct regions of the transcription factor CP2. The FEBS journal 18 15720400
2005 Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. Journal of virology 18 15857981
2017 MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth. Oncotarget 17 29423052
1999 Transcription factor CP2 is crucial in hemoglobin synthesis during erythroid terminal differentiation in vitro. Biochemical and biophysical research communications 16 10491335
2022 Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review. Histopathology 15 36350070
1997 Regulation of the secretion and synthesis of rat Sertoli cell SGP-1, SGP-2 and CP-2 by elongate spermatids. International journal of andrology 15 9354187
2023 Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature. Histopathology 14 38114270
2022 Rhabdomyosarcoma With FUS::TFCP2 Fusion in the Scalp: A Rare Case Report Depicting Round and Spindle cell Morphology. International journal of surgical pathology 14 36437645
2016 Grifolin inhibits tumor cells adhesion and migration via suppressing interplay between PGC1α and Fra-1 / LSF- MMP2 / CD44 axes. Oncotarget 14 27626695
2005 Further evidence for LBP-1c/CP2/LSF association in Alzheimer's disease families. Journal of medical genetics 14 16272261
2022 Intraosseous Spindle Cell/Epithelioid Rhabdomyosarcoma with TFCP2 Rearrangement: A Recent Recognized Subtype with Partial Response to Alectinib. International journal of surgical pathology 13 36474403
2021 TFCP2 Overcomes Senescence by Cooperating With SREBP2 to Activate Cholesterol Synthesis in Pancreatic Cancer. Frontiers in oncology 13 34804919
2020 Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence. BMC cancer 13 32539694
2020 Differential Analysis of Stress Tolerance and Transcriptome of Probiotic Lacticaseibacillus casei Zhang Produced from Solid-State (SSF-SW) and Liquid-State (LSF-MRS) Fermentations. Microorganisms 12 33114487
2007 Potential interaction between the GARS-AIRS-GART Gene and CP2/LBP-1c/LSF transcription factor in Down syndrome-related Alzheimer disease. Cellular and molecular neurobiology 12 17902044
2023 Cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion: A case report emphasizing early detection. Journal of cutaneous pathology 11 37669767
2022 circITCH suppresses cell proliferation and metastasis through miR-660/TFCP2 pathway in melanoma. Cancer medicine 11 35274492
2022 TFCP2, a binding protein of ATF3, promotes the progression of glioma by activating the synthesis of serine. Experimental cell research 11 35421367
2014 Expression of TSG101 protein and LSF transcription factor in HPV-positive cervical cancer cells. Oncology letters 11 24765146
2006 Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression. Dementia and geriatric cognitive disorders 11 16710089
2004 Transcription factor CP2 is involved in activating mBMP4 in mouse mesenchymal stem cells. Molecules and cells 11 15232220
2024 Diagnostic and Therapeutic Implications of a FUS::TFCP2 Fusion and ALK Activation in a Metastatic Rhabdomyosarcoma. Genes, chromosomes & cancer 10 39302072

Missed literature

Know a paper Affinage missed for TFCP2? Flag it for the maintainers and the community.

No submissions yet.